In their CKD mouse model fed with adenine-containing diet, the roxadustat cohort showed more marked lowering of FGF23 production and increasing vitamin D 1α-hydroxylase (Cyp27b1) expression compared to the EPO cohort, greatly rescuing the imbalanced mineral metabolism and opening up a new avenue for therapy of hyperparathyroidism and metabolic bone diseases. Here, EPO is linked to chronic kidney disease.